Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer-Reference-Cited by-同舟云学术

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Xiang Hong¹²^ORCID,Chan Abigael G.¹³,Ahene Ago¹⁴,Bellovin David I.¹⁵,Deng Rong⁶,Hsu Amy W.¹⁷,Jeffry Ursula¹⁸,Palencia Servando¹⁹,Powers Janine¹¹⁰,Zanghi James¹¹¹,Collins Helen¹¹²

Affiliation:

1. Five Prime Therapeutics, Inc, South San Francisco, California

2. Clinical Pharmacology, Modeling and Simulation, Amgen Inc, South San Francisco, California

3. Global Project Management, Amgen Inc, South San Francisco, California

4. Bioanalytic Sciences, Amgen Inc, South San Francisco, California

5. Biology, Zai Lab (US) LLC, Menlo Park, California

6. R&D Q-Pharm Consulting LLC, Pleasanton

7. Merck and Co., South San Francisco, California

8. Toxicology Department, NGM Biopharmaceuticals, Inc, South San Francisco, California

9. Research, Teva Pharmaceuticals, Redwood city, California

10. Translational Medicine, Nurix Therapeutics, San Francisco, California

11. Bioanalytic Sciences, Genentech Inc., South San Francisco, California

12. Clinic, Amgen Inc., South San Francisco, California

Funder

not funded

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2021.1981202

Reference38 articles.

1. The Role of Fibroblast Growth Factors in Tumor Growth

2. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.

3. Developmental Localization of the Splicing Alternatives of Fibroblast Growth Factor Receptor-2 (FGFR2)

4. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes.

5. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

2. Protein isoform-centric therapeutics: expanding targets and increasing specificity;Nature Reviews Drug Discovery;2024-09-04

3. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis;Gastric Cancer;2024-06-11

4. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

5. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care;American Society of Clinical Oncology Educational Book;2024-06